Stockwinners Market Radar for November 12, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:57 EDT Viking Therapeutics says VK2809 study achieves primary, secondary endpoints - Viking Therapeutics announced the presentation of results from the company's 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. As previously reported, the study successfully achieved both its primary and secondary endpoints, and demonstrated an encouraging safety and tolerability profile. Newly presented data provide further detail on the trial endpoints, highlighting the changes to LDL-C, atherogenic proteins, and other liver parameters. The results were presented Monday, November 12 as part of the Oral Late-Breaker session of The Liver Meeting 2018, the annual meeting of the American Association for the Study of Liver Diseases, held November 9-13 in San Francisco, CA.

18:31 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: Huya Inc (HUYA) up 8.1%... Medallian Financial (MFIN) up 3.7%. DOWN AFTER EARNINGS: Eventbrite (EB) down 6.8%... Yirendai (YRD) down 4.7%... Kornit Digital (KRNT) down 0.8%. ALSO LOWER: Maiden Holdings (MHLD) down 4.2% after reports that Catalina will not bid for company... Sage Therapeutics (SAGE) down 2.3% after being initiated at Underperform at Leerink.

18:03 EDT Pareteum to acquire iPass in all-stock transaction - Pareteum (TEUM) and iPass (IPAS) announced that they have entered into a denitive agreement under which Pareteum will acquire iPass in an all-stock transaction whereby iPass shareholders will receive 1.17 shares of Pareteum common stock in an exchange offer. With this accretive acquisition, Pareteum expects to gain a strategic position with new marquee brands and new markets including the enterprise, airline, hospitality, retail and internet of things sectors. Pareteum expects to strengthen its established intellectual property portfolio with the addition of over 40 U.S. and international patents. With more than 500 expected new customers and a global network of over 68M Wi-Fi hot spots, coupled with proven connection management technology, location services and Wi-Fi performance data, Pareteum is now poised to take its global communications software solutions to every market vertical. The transaction is expected to be immediately accretive to Pareteum's non-GAAP EPS and free cash ow after anticipated synergies. Pareteum anticipates achieving more than $15 million in annual cost synergies with greater than $12 million of those expected to be realized in the rst full quarter of combined operations. Pareteum currently estimates approximately $2.0 million of GAAP earnings accretion and $5.5 million of non-GAAP earnings accretion in the rst full year after closing the transaction. In addition, the acquisition will add new offices and talent in Silicon Valley, California and Bangalore, India, expanding Pareteum's presence globally. Under the terms of the denitive acquisition agreement, a wholly-owned subsidiary of Pareteum will commence an exchange offer to acquire all of the outstanding shares of iPass common stock, offering 1.17 shares of Pareteum common stock in exchange for each share of iPass common stock tendered. Upon satisfaction of the conditions to the exchange offer, and after the shares tendered in the exchange oer are accepted for payment, the agreement provides for the parties to effect, as promptly as practicable, a merger, which would not require a vote by iPass stockholders, and which would result in each share of iPass common stock not tendered in the exchange offer being converted into the right to receive 1.17 shares of Pareteum common stock. The exchange offer is subject to customary conditions, including the tender of at least a majority of the outstanding shares of iPass common stock and certain regulatory approvals, and is expected to close in the rst quarter of calendar year 2019. No approval of the stockholders of Pareteum is required in connection with the proposed transaction. Terms of the agreement were approved by the board of directors for both Pareteum and iPass.

17:54 EDT Nvidia reports record adoption of new Turing T4 GPU - Nvidia announced that the new T4 GPU has received the fastest adoption of any server GPU. Two months after its introduction, the T4 is featured in 57 separate server designs from the world's leading computer makers. It is also now available in the cloud, with the first availability of the T4 for Google Cloud Platform customers.

17:34 EDT Huya reports Q3 average mobile MAUs 49.4M, up 28.2% from last year - Q3 Average MAUs reached 99.0M, representing an increase of 14.6% from 86.3M last year. Q3 total number of paying users reached 4.2M, representing an increase of 37.8% from last year.

17:25 EDT Roan Resources sees Q4 production 52-56 MBoe/d - The Company is projecting fourth quarter 2018 production to range between 52 and 56 MBoe/d, with total liquids at approximately 57% and the fourth quarter exit rate between 58 and 62 MBoe/d. Full-year 2018 production is expected to be between 43 and 44 MBoe/d, in-line with previous guidance. Fourth quarter 2018 operating expenses are projected to be lower than the third quarter results. LOE is expected to be between $2.60 and $2.90 per Boe and cash G&A (non-GAAP) is expected to be between $2.10 and $2.40 per Boe. Fourth quarter capital expenditures are expected to be between $200 million and $225 million. Therefore, total capital expenditures for 2018 are now expected to be between $760 million and $785 million, which includes $110 million to $115 million in other capital expenditures. This is an increase to previously provided guidance due to costs attributable to wells drilled and completed from the predecessor companies, adding an eighth rig earlier than originally planned and higher completion costs as the company tests different completion designs.

17:19 EDT Intel accelerates launch of multimode modem to support 5G rollouts - Intel announced the Intel XMM 8160 5G modem, a multimode modem optimized to provide 5G connectivity to devices like phones, PCs and broadband access gateways. Intel has accelerated the timing of this modem by pulling in the launch by more than a half-year. The XMM 8160 5G will support peak speeds up to 6 gigabits per second, making it three to six times faster than the latest LTE modems available today. It will be available in the second half of 2019 and will deliver the features and experiences to accelerate widespread 5G adoption. The Intel XMM 8160 is a multimode modem, meaning it will support the new standard for 5G New Radio (NR), including standalone and non-standalonemodes, as well as 4G, 3G and 2G legacy radios in a single chipset. The Intel XMM 8160 5G modem is expected to ship in the second half of 2019. Commercial devices using the Intel XMM 8160 5G modem including phones, PCs and broadband access gateways are expected to be available in the first half of 2020.

17:02 EDT Source Capital declares $3.20 per share special dividend - Source Capital declared a $3.20 per share special dividend, payable on December 15 to shareholders of record as of November 30.

16:49 EDT Energizer names Patrick Moore chairman of the board - Energizer Holdings announced that its board of directors elected Patrick J. Moore, currently vice chairman of the board of directors, as independent chairman of the board of directors, effective immediately. Moore succeeds J. Patrick Mulcahy, who served as Energizer's independent chairman since July 2015. Mulcahy will continue to serve as a member of the board.

16:35 EDT W.R. Grace to increase price for silica-based, molecular sieve products by 7% - W. R. Grace will increase the price of silica-based and molecular sieve products sold through its Grace Materials Technologies business segment by 7% as contracts allow. This pricing action will enable Grace to sustain investment in manufacturing capabilities and increase R&D on technologies to help customers produce differentiated products and meet more stringent regulatory requirements across a broad spectrum of industries. This increase will be effective January 1, 2019. Grace's silica-based and molecular sieves technologies are used in manufacturing processes and as additives in customers' end products over a wide range of applications from coatings and plastics to food and pharmaceuticals.

16:33 EDT AXA Equitable announces $300M stock repurchase program

16:31 EDT Elevate Credit appoints David Peterson Chief Credit Officer - Elevate Credit announced that it has appointed David Peterson as Chief Credit Officer, effective immediately. Peterson's background includes 15 years' experience in financial services, primarily in credit risk. He joined the company in 2010 and has held a number of roles of increasing responsibility in areas including credit strategy, risk, portfolio management and fraud. Previously he was with Americredit Financial Services.

16:26 EDT HFF arranges a $414.5M JV for 20 high-quality retail centers - Holliday Fenoglio Fowler announces that it acted as exclusive financial advisor to Phillips Edison & Company and its affiliate in facilitating the formation of Grocery Retail Partners I and Grocery Retail Partners II , two joint venture partnerships totaling $414.5 million in asset value and encompassing 20 high-quality, grocery-anchored shopping centers in what is the largest shopping center recapitalization of the year. Working on behalf of PECO and Phillips Edison Grocery Center REIT III, , which is a REIT sponsored and managed by PECO, the HFF team arranged GRP I and GRP II JVs with Northwestern Mutual as the partner. Under the terms of GRP I, Northwestern Mutual acquired an 85-percent interest in the 17-center portfolio, which is currently valued at $368 million. PECO maintained 15-percent ownership in the portfolio while providing asset and property management services for the joint venture. The proceeds from GRP I will be deployed by PECO to delever its balance sheet, fund redevelopment projects and further expand its portfolio of grocery-anchored centers. Under the terms of GRP II, Northwestern Mutual invested in three shopping centers currently owned by PECO III. Northwestern Mutual acquired a 90-percent interest in the portfolio, which is valued at approximately $46.5 million, and PECO III maintained a 10-percent ownership in the portfolio. PECO, as PECO III's sponsor and manager, will continue to provide asset and property management services for the properties. PECO III intends to use the proceeds to further expand its growing portfolio of grocery-anchored centers. The HFF equity placement team representing PECO and PECO III included senior managing directors Steve Hentschel and Danny Finkle and senior director Sheheryar Hafeez along with senior managing directors Michael Joseph and Doug Bond.

16:21 EDT Invesco reports preliminary AUM $926.1B as of October 31, down 5.6% - The decrease was driven by unfavorable market returns, net long-term outflows, foreign exchange, and non-management fee earning AUM outflows; partially offset by higher money market AUM and reinvested distributions.

16:19 EDT Lantronix announces availability of XPort Edge - Lantronix announced the general availability of its XPort Edge embedded ethernet IoT gateway. Since its introduction, the XPort serial to ethernet device server has been a module used by OEMs to add network connectivity to industrial devices. To date, millions of IoT enabled devices have been deployed in the market using XPort, and every year that number grows by hundreds of thousands of units. XPort Edge brings a new level of performance, enhanced security, pre-integrated device management capability and cloud connectivity to this platform.

16:18 EDT Kellogg announces changes to KNA organizational structure - To increase agility, Kellogg is making four primary changes to its KNA organizational structure: Consolidating U.S. Morning Foods, Snacks and Frozen Foods business units into a single, categories-focused organization comprising 80 percent of KNA revenue; Combining Morning Foods, Snacks and Frozen and Retail Channels sales teams within a single Kellogg U.S. sales organization to improve customer focus; Building a consolidated, end-to-end KNA Supply Chain including procurement, manufacturing, logistics, and customer service to increase scale, enhance capability and ensure delivery of the company's growth goals; and, Investing in new eCommerce and Integrated Business Planning capabilities."Successfully achieving our Deploy for Growth Strategy in KNA requires that we grow our business through strong commercial ideas and innovation, prioritized investment choices, excellence in execution and increased speed-to-market," said Chris Hood, President, Kellogg North America. "We are confident the changes we are putting in place will help us achieve these objectives."

16:16 EDT Waddell & Reed reports AUM of $72.2B as of October 31st vs. $79.5B last month

16:07 EDT Manning & Napier reports preliminary AUM $21.3B as of October 31 - Compared with $23.1B at September 30, 2018.

16:02 EDT Colliers International to acquire former affiliate of CBRE Group in Virginia - Colliers International Group announced it has agreed to acquire a majority interest in the operations of the former affiliate of CBRE Group, in Central and Southeast Virginia, which will be rebranded as Colliers International Virginia. The current shareholders of Colliers Virginia will continue to retain equity in the business under the unique Colliers partnership model. During the interim period, Colliers will work with its existing affiliate to integrate its operations into Colliers Virginia. Terms of the transaction were not disclosed, and the transaction is subject to customary closing conditions and expected to close by Q1 of 2019.

13:54 EDT Amarin CEO says focused on execution after capital raise earlier this year - John Thero is speaking on CNBC.

13:40 EDT American Cable Association asks DOJ for investigation of Comcast-NBCU - The American Cable Association has asked antitrust law enforcers at the Department of Justice to open an investigation into the business practices of Comcast-NBCU, "focusing on harms stemming from the dominant communications firm's control of cable systems, TV stations, and regional sports networks concentrated in some of the largest local markets in the country." The agency's request came in a Nov. 6 letter to Makan Delrahim, Department of Justice's Assistant Attorney General for Antitrust. In the letter, ACA and its members "pledged to cooperate fully to assist in the investigation, including by providing information about Comcast-NBCU's practices." "By opening a formal investigation, the DOJ, which has already put Comcast-NBCU on notice, can take the next step to gather facts about the company's activities and ensure consumers and competition are protected. Given the enormity of Comcast-NBCU's market presence and incentive to engage in anticompetitive harm, such an investigation is fully warranted," ACA President and CEO Matthew Polka said in statement. President Trump highlighted the ACA's request this afternoon in a tweet. Shares of Comcast are down 30c to $38.04 in afternoon trading. Reference Link

13:20 EDT Facebook experiencing service issues - Visiting Facebook.com currently returns the following message: "Sorry, something went wrong. We're working on it and we'll get it fixed as soon as we can." Additionally, crowd-sourced service monitoring site "downrightnow" indicated reports of Facebook service disruptions.

12:45 EDT Avangrid names Peter Church chief HR officer - Avangrid (AGR) announced the appointment of Peter Church as Chief Human Resources Officer. In this role, Church will oversee Human Resources, Information Technology and General Services. Reporting to Avangrid CEO James Torgerson, Church will be responsible for developing and executing human resource strategies in support of the overall company business plan and strategic direction of the organization. Church comes to Avangrid from UnitedHealthcare (UNH), where he was Chief Talent Officer responsible for creating, leading and driving talent strategies, ensuring the ongoing and successful attraction, development and engagement of a world class workforce.

12:02 EDT Motorola Solutions selects Microsoft Azure Government cloud for Command - Motorola Solutions (MSI) announced that it has selected Microsoft (MSFT) Azure Government as the cloud provider for its public safety software suite. Azure Government provides the flexibility and security that public safety agencies require as they adopt cloud-based public safety software. Motorola Solutions' comprehensive public safety software suite helps agencies work smarter and more efficiently from call to case closure helping to keep communities safe.

12:00 EDT PG&E falls -15.8% - PG&E is down -15.8%, or -$6.30 to $33.62.

12:00 EDT ProShares Trust Ultra VIX Short Term Futures ETF rises 9.2% - ProShares Trust Ultra VIX Short Term Futures ETF is up 9.2%, or $4.57 to $54.56.

12:00 EDT Best Inc. rises 17.0% - Best Inc. is up 17.0%, or 88c to $6.07.

11:32 EDT Employers names Lori Brown chief legal officer, general counsel - EMPLOYERS has named Lori Brown as EVP, chief legal officer and general counsel for EMPLOYERS effective January 1, 2019. Brown joined EMPLOYERS in January 2006 and served as VP, deputy general counsel until March 2015 when she was promoted to SVP. As part of her responsibilities, Brown currently serves as a director of Employers Group, is the assistant corporate secretary to Employers Holdings, and is the corporate secretary to all of the company's subsidiary companies. Brown will be replacing Lenard Ormsby in the position upon his retirement.

11:17 EDT Third Point releases video introducing Short Slate for Campbell's board - Third Point, a holder of approximately 7% of the outstanding common shares of Campbell Soup Company, released a new video introducing its Independent Short Slate candidates: Sarah Hofstetter, Munib Islam, William Toler, Bozoma Saint John and Kurt Schmidt. The firm said, "In the four-minute video, our highly-qualified nominees discuss what has gone wrong at Campbell and their enthusiasm for serving shareholders to #RefreshTheRecipe at the company. We also encourage all shareholders to once again review our Case for Change to understand more about why Third Point's nominees are well-positioned to turn around Campbell. We urge all shareholders to VOTE THE WHITE CARD to elect the entire Independent Short Slate."

10:43 EDT Trump says 'Presidential Harassment by the Dems' hurting stocks - President Donald Trump tweeted this morning, "The prospect of Presidential Harassment by the Dems is causing the Stock Market big headaches!"

10:32 EDT Izea expands SaaS relationship with Fortune 500 electronics manufacturer - IZEA Worldwide announced that a Fortune 500 electronics manufacturer has broadened its relationship with IZEA and signed a commitment to increase its marketplace spend through the company's technology platforms. The customer relationship was originally established as part of the acquisition of TapInfluence. IZEA continues to see an increase in marketplace activity through the IZEAx and TapInfluence platforms. Combined marketplace bookings in TapInfluence and IZEAx increased more than 20% year over year during the month of October.

10:15 EDT Rockwell Automation, PTC launch FactoryTalk InnovationSuite - Rockwell Automation (ROK) and PTC (PTC) announced that they have launched FactoryTalk InnovationSuite, powered by PTC, a software suite that enables companies to optimize their industrial operations and enhance productivity by providing decision makers with improved data and insights. The new suite delivers complete visibility of operations and systems status from one source of information inside the organization. The collaborative offering is the first to integrate technologies from both companies following the strategic partnership announcement in June. FactoryTalk InnovationSuite, powered by PTC, improves connectivity to operational technology devices on the plant floor, natively supporting the rapid, scalable, and secure connection of the most commonly used industrial equipment. Combined with data from information technology applications and systems, decision makers can now gain a complete digital representation of their industrial equipment, lines, and facilities from anywhere in the enterprise.

10:00 EDT Edison International falls -17.1% - Edison International is down -17.1%, or -$10.44 to $50.56.

10:00 EDT PG&E falls -27.0% - PG&E is down -27.0%, or -$10.78 to $29.14.

10:00 EDT Lannett rises 8.2% - Lannett is up 8.2%, or 44c to $5.80.

09:59 EDT General Electric shares drop below $8 after CEO interview on CNBC

10:00 EDT Viacom's MTV acquires SnowGlobe Music Festival, terms not disclosed - MTV expanded its global live events business into the U.S. with the acquisition of SnowGlobe Music Festival, the nation's premier outdoor New Year's Eve music festival. The annual, three-day event takes place December 29-31 in South Lake Tahoe, California and welcomes more than 20,000 fans each day with a mix of musical performances, live action sports, and interactive art exhibitions. Artists from Kendrick Lamar to Post Malone to Zedd and many more have performed at SnowGlobe, which is highlighted by its iconic countdown party at midnight on New Year's Eve. Terms of the deal were not disclosed. MTV is a unit of Viacom.

10:00 EDT Viacom's MTV acquires SnowGlobe Music Festival, terms not disclosed - MTV expanded its global live events business into the U.S. with the acquisition of SnowGlobe Music Festival, the nation's premier outdoor New Year's Eve music festival. The annual, three-day event takes place December 29-31 in South Lake Tahoe, California and welcomes more than 20,000 fans each day with a mix of musical performances, live action sports, and interactive art exhibitions. Artists from Kendrick Lamar to Post Malone to Zedd and many more have performed at SnowGlobe, which is highlighted by its iconic countdown party at midnight on New Year's Eve. Terms of the deal were not disclosed. MTV is a unit of Viacom.

09:47 EDT Edison International falls -17.1% - Edison International is down -17.1%, or -$10.44 to $50.56.

09:47 EDT PG&E falls -25.9% - PG&E is down -25.9%, or -$10.32 to $29.60.

09:47 EDT VelocityShares 3x Long Natural Gas ETN rises 5.0% - VelocityShares 3x Long Natural Gas ETN is up 5.0%, or $6.05 to $127.97.

09:45 EDT Cumulus Media Inc (Class A Stock) trading halted, volatility trading pause

09:37 EDT Third Point seeks more detail on Campbell's process for adding board members - Third Point, a holder of approximately 7% of the outstanding common shares of Campbell Soup Company, sent a letter to Keith McLoughlin, Campbell's CEO, in response to the company's press release on Friday afternoon. The letter read, "On Friday, Campbell disclosed publicly the existence of our private settlement talks. We were pleased that your statement acknowledged that changes to the Board would be beneficial and that the Independent Short Slate nominees are well-qualified to contribute to a refreshed recipe at Campbell. This is an important point of agreement and reflects shareholders' similar desire for a combined Board. Nevertheless, we were disappointed that you chose to share our private negotiations via a press release, as we believed that our limited conversations were confidential. As you are aware, there have been only a handful of phone calls between the Board, your advisors, and Third Point since this contest began. The last call was on Friday afternoon, shortly before you issued your public release. This point aside, we were particularly interested in your comments about the types of directors you are seeking to add to the Board and your embrace of two of our candidates, Kurt Schmidt and Sarah Hofstetter. In previous proxy contests, our candidates have gladly engaged in appropriate diligence, most often meeting other Board members and/or the Company's leadership face-to-face. Since you have not pursued this process to date, despite our entreaties to meet, we would be interested to learn how you are making decisions about which members of the Independent Short Slate would best serve shareholders. For example, in proxy contests today, it is the norm for a shareholder activist to join a Board to bring expertise in capital allocation and markets at a time of change for a Company. Many other Boards have agreed to this arrangement and found ways to manage any apparent conflict. Your process and framework for Board selection would be helpful transparency to provide to shareholders. We are pleased that change is on the horizon at Campbell and look forward to resolving this proxy contest soon."

09:33 EDT PG&E trading halted, volatility trading pause

09:30 EDT General Electric CEO says 'no plans' for an equity raise - Culp said the company could reconsider that in the future, but GE currently has no plans for an equity raise. Larry Culp made the comments in an interview on CNBC.

09:29 EDT ARCA Biopharma announces data from AFB substudy of GENETIC-AF trial at AHA - ARCA Biopharma announced that data from the Atrial Fibrillation Burden, or AFB, substudy of the Phase 2B GENETIC-AF clinical trial were presented in a poster session at the American Heart Association, or AHA. GENETIC-AF was a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro as a genetically-targeted treatment for atrial fibrillation, or AF, in patients with heart failure and reduced left ventricular ejection fraction, or HFrEF. Safety data indicated that Gencaro was generally safe and well-tolerated in the AF/HFrEF population investigated with a safety profile similar to the active comparator metoprolol succinate. The primary endpoint results for the trial were determined by intermittent, clinic-based heart rhythm monitoring. However, a subset of patients also underwent continuous heart rhythm monitoring with Medtronic implanted devices to determine AF recurrence based on AFB, a method that can identify AF with more certainty than intermittent clinic-based monitoring. A prespecified time-to-first event analysis was conducted using a total AFB of at least 6 hours per day to define an event of AF recurrence, as this criterion has been previously shown to be associated with an increased rate of HF hospitalizations. In this substudy, Gencaro demonstrated similar trends for benefit compared to Toprol-XL for the endpoint of time to AF recurrence when measured by continuous monitoring with implanted devices and by intermittent ECG-based monitoring. Event rates were slightly higher for device-based monitoring and the device-based endpoint occurred a median of 6.5 days prior to ECG-based detection. Analyses were also presented for a cohort that exclude patients with long-standing and heavily pretreated HF and/or AF. In these analyses, a trend for benefit in favor of Gencaro over Toprol-XL was observed in the overall population and in the AFB substudy population using device-based detection and ECG-based detection.

09:23 EDT GE CEO says aviation the 'crown jewel,' but all options will be considered - GE CEO Larry Culp continues being interviewed on CNBC.

09:20 EDT Fly Intel: Pre-market Movers - HIGHER: Apptio (APTI), up 52% after announcing it will be acquired by Vista Equity Partners for $38 per share... Athenahealth (ATHN), up 9% after confirming that Veritas and Elliott will acquire the company for $135 per share... Lannett (LCI), up 5% after entering into an exclusive agreement with Amneal Pharmaceuticals (AMRX) for Levothyroxine sodium tablets... L Brands (LB), up 3% after being upgraded to Outperform from Market Perform at Wells Fargo. DOWN AFTER EARNINGS: Qutoutiao (QTT), down 10%... Autohome (ATHM), down 2%. ALSO LOWER: PG&E (PCG), down 15% amid ongoing California wildfires... Altria Group (MO) and Brtish American Tobacco (BTI), down 4% and 7%, respectively, after the Wall Street Journal reported that the FDA plans to propose a ban on menthol cigarettes... SAP (SAP), down 5% after announcing a deal to acquire survey company Qualtrics for $8B in cash.

09:16 EDT General Electric CEO says will look at all options with 'urgency' - General Electric (GE) CEO Larry Culp said the company will look at all its options with "urgency," including its options for its Baker Hughes (BHGE) stake, but will not make rash decisions that will be mistakes over the long-term. Culp continues speaking on CNBC.

09:15 EDT Xeris releases additional Phase 3 trial data on ready-to-use glucagon pen - Xeris Pharmaceuticals announced the presentation of additional data supporting the efficacy and functional utility of its investigational ready-to-use, room-temperature stable liquid glucagon pen during the 18th Annual Diabetes Technology Meeting in North Bethesda, MD, November 8-10, 2018. The additional data supported the company's recent filing to the FDA for regulatory approval. The data from three posters provide a closer look at the ease of use and effectiveness of the Xeris investigational glucagon pen as an alternative to currently marketed rescue systems, which require complex, multi-step preparation and administration processes. These data outline the glucagon pen's efficacy in prompt and complete resolution of hypoglycemia in both adults and children with diabetes, as well as simplicity to facilitate successful administration during these critical settings.

09:12 EDT General Electric CEO says retail investors exiting stock after dividend cut - General Electric CEO Larry Culp says dividend cut is being followed by retail investors exiting, but it was still the right long-term decision. Culp is being interviewed on CNBC.

09:06 EDT Hi-Crush Partners enters into frac, sand supply agreement with Chesapeake Energy - Hi-Crush Partners announced that it has entered into a new, long-term frac sand supply agreement for the in-basin purchase of Northern White frac sand to support Chesapeake Energy and their completions program in the Marcellus and Powder River Basins. In addition, Chesapeake will utilize one PropStream container crew and related logistics with the option to expand based on demand.

09:02 EDT eBay announces partnerships with Handy, Porch and InstallerNet - eBay announced partnerships with leading service providers Handy, Porch and InstallerNet, which will allow shoppers to easily book installation services on a massive selection of eBay inventory. When purchasing items that require installation or assembly, eBay shoppers will have the ability to add a service from the most appropriate provider as part of the checkout process. Handy, Porch and InstallerNet offer a wide array of services, and each will connect eBay shoppers with pre-screened local service professionals across the United States.

08:52 EDT PPG, Powercast announce joint development agreement - PPG and Powercast Corporation announced a joint development agreement to produce ultra-thin and wirelessly powered printed electronics products. The advanced solutions combine PPG TESLIN substrate, PPG conductive inks and Powercast's POWERHARVESTER receiver technology for delivering over-the-air wireless power. Powercast and PPG will introduce LED-based wireless illumination solutions for smart consumer packaging and smart identification cards, which enable enhanced security. "The technology sharing between PPG and Powercast is an excellent example of the type of collaboration that continues to strengthen PPG. We see this partnership as an ideal way to use the unique synergies of our broad portfolio of coatings and materials technologies to help our customers find solutions," said John Yundt, PPG global market manager, electronic and conductive materials.

08:45 EDT ElectraMeccanica announces carsharing partnership with Chantrell Creek Estates - ElectraMeccanica announced a partnership with Engel & Volkers' proposed Chantrell Creek Estates residential development in British Columbia, Canada to introduce a Solo electric vehicle carsharing program to provide future residents with greater mobility options in a city that is currently beset with traffic congestion problems and the lack of an effective public transit system. Chantrell Creek Estates is a new residential development that seeks to provide a combination of gentle densification, entry-level housing for younger families as well as downsizing opportunities for established residents in the area. It also seeks to improve the quality of life in the area by preserving the area's most prized features while progressively tackling real issues that face the area like congestion and access to public transportation.

08:42 EDT Cellectar Biosciences announces FDA exemption to import alert for CLR 131 - Cellectar Biosciences announced that the FDA has granted an exemption to the import alert placed on the Centre for Probe Development and Commercialization, or CPDC, the sole supplier of the CLR 131. The exemption for CLR 131 is effective immediately for all hematology studies and, in response, Cellectar is preparing to dose patients in the second fractionated dose cohort of the Phase 1 relapsed refractory, or R/R, multiple myeloma study and the Phase 2 study for R/R hematologic malignancies. The company awaits authorization from the FDA for any future shipments in connection with its Phase 1 study of pediatric patients with neuroblastoma, sarcomas, lymphomas and malignant brain tumors.

08:39 EDT VistaGen Therapeutics receives notices of allowance from IP Australia, JPO - VistaGen Therapeutics announced receiving notices of allowance from IP Australia and the Japan Patent Office, or JPO, related to methods of treating depression with AV-101, VistaGen's oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.

08:38 EDT Marvell awarded funding from Los Alamos National Laboratory - Marvell announced that it has been awarded funding from Los Alamos National Laboratory to accelerate the architecture, design and development of advanced server technology required for more efficient usable operations per second per watt or operations per second per dollar of programmer time. With this funding, Marvell will focus on advancing key areas of system architecture and silicon design that maximize the efficiency and overall performance of large-scale supercomputers that are critical for the most demanding and complex problems in science and research. Key technology elements to be addressed include processor core design, enhanced memory technology and optimized processor interconnect architecture.

08:37 EDT Theravance Biopharma says EC authorizes expanded label for Trelegy Ellipta - Theravance Biopharma (TBPH) highlighted that the European Commission authorized an expanded label for once-daily Trelegy Ellipta, recognizing the product's effect on exacerbations and making it the first single-inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease not adequately treated with dual bronchodilation or with an inhaled corticosteroid and a long-acting beta2-agonist. Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innoviva. Theravance Biopharma is entitled to receive an 85% economic interest in the royalties paid by GSK on worldwide net sales. Those royalties are upward-tiering from 6.5% to 10%, resulting in cash flows to Theravance Biopharma of approximately 5.5% to 8.5% of worldwide net sales of Trelegy Ellipta.

08:33 EDT Brown & Brown Massachusetts acquires Rodman Insurance Agency - Brown & Brown announced that Brown & Brown of Massachusetts has acquired substantially all of the assets of Rodman Insurance Agency. Rodman Insurance Agency specializes in providing property and casualty insurance products and services to commercial customers in the real estate, habitational, restaurant, and transportation industries. The firm has annual revenues of approximately $9.5M and primarily supports customers in Massachusetts and throughout the Northeast. Following the acquisition, the Rodman Insurance Agency team will continue operating from its existing Needham, Massachusetts office under the leadership of Andy Altman.

08:31 EDT Athenahealth to be acquired by Veritas Capital for $135 per share in cash

08:22 EDT Organovo partners with IIAM on clinical sourcing agreement - Organovo announced that it has entered into a cell and tissue clinical sourcing agreement with the International Institute for the Advancement of Medicine, or IIAM. Under the terms of the agreement, IIAM will provide Organovo with donated organs that have not been utilized for transplantation with high potential benefit for generating the cell-based building blocks for Organovo's therapeutic liver tissue development program.

08:15 EDT MagneGas announces $1.05M in sales for October - MagneGas announced that the company generated sales of $1.05M for the month of October, as compared to $370,000 in October 2017, representing a 180% increase. The sales growth was a result of MagneGas' expansion into California, Texas and Louisiana through six acquisitions made. The fastest growing market for the company in October was the Texas and Louisiana combined market, which grew 68% compared to September sales. This was in part the result of three acquisitions made in the second half of October, which doubled the company's retail store count and added a market presence in Paris, Texas and Longview, Texas. The company saw its second fastest growth in the southern California market, where sales grew 15% compared to September results. This market continues to show strength and has been very receptive to both the sales of the MagneGas metal cutting fuel product, as well as strong new client adoption and cross sales activities. The third fastest growing market for the company was in Florida, which saw a 9% increase compared to September sales. The company has benefitted from expanded marketing efforts in the Tampa and Pasco County region with the addition of a 4th retail location in that market. From a revenue comparison perspective, the company's northern California operations are the largest contributor to overall company revenues. As the company's largest and most mature market, it typically is expected to grow at a more stable, sustained rate. The company continues to see strong expansion into the medical and cannabis markets, and grew at a 5% growth rate compared to September sales.

08:13 EDT Choice Hotels to develop new Cambria Hotel in Alpharetta, Georgia - Choice Hotels has signed an agreement with an affiliate of HB Capital Management LLC, to develop a Cambria Hotel in Alpharetta, Georgia. The five-story, 144-room upscale hotel is slated to open in 2020.

08:10 EDT Nuance sells document imaging division to Kofax for $400M - Nuance announced the company has signed a definitive agreement to sell its document imaging division to Kofax. The sale enables Nuance to focus the business entirely on its conversational AI- and cloud- based solutions while simplifying the organization and improving its growth profile. For Kofax, the Document Imaging division bolsters the company's Intelligent Automation technologies. Total consideration for the transaction is $400M in cash. The deal, which is subject to customary closing conditions, is expected to close by the end of Nuance's second fiscal quarter.

08:08 EDT Legg Mason reports preliminary AUM approximately $733B as of October 31

08:07 EDT Aimmune announces additional $98M equity investment by Nestle Health Science - Aimmune Therapeutics (AIMT) announced that Nestle Health Science (NSRGY) will make an additional equity investment in Aimmune of $98M, increasing Nestle Health Science's ownership of Aimmune to approximately 19%. This $98M investment brings Nestle Health Science's total investment in Aimmune to $273M Nestle Health Science first invested $145M in Aimmune in November 2016, followed by $30M as part of Aimmune's public offering in February 2018. Aimmune and Nestle Health Science also entered into a two-year extension of their original two-year strategic collaboration agreement, focused on offering innovative food allergy therapies. The agreement does not contain any partnership, collaboration, or negotiation restrictions on Aimmune. Aimmune retains all rights to its current and future pipeline assets, and Aimmune and Nestle Health Science will collaborate towards successful development of such assets. The investment adds a two-year extension to the original two-year strategic collaboration between Aimmune and Nestle Health Science launched in November 2016. Through the continuation of the Strategic Collaboration Committee, Aimmune and Nestle Health Science will engage broadly on Aimmune's current and future development programs, leveraging Nestle Health Science's scientific, regulatory, and commercial expertise. Upon closing of the equity investment, Aimmune will receive a payment of $98M in connection with Nestle Health Science's purchase of 3,237,529 newly issued shares of Aimmune's common stock at $30.27 per share, priced at a five-day volume adjusted trading average. After the completion of the transaction, Nestle Health Science's total investments in Aimmune will correspond to an 18.9% stake in the company. The companies expect to close the equity investment by the end of 2018, subject to the expiration or termination of applicable waiting periods under all applicable antitrust laws and satisfaction of other usual and customary closing conditions.

08:06 EDT Praxair signs long-term agreement to supply oxygen to Fulcrum BioEnergy - Praxair, a wholly-owned subsidiary of Linde, announced it has signed a long-term agreement to supply oxygen to Fulcrum BioEnergy's Sierra BioFuels Plant in Storey County, Nevada. Praxair will build two vacuum pressure swing adsorption plants at the facility, which is under construction and expected to start up operations in early 2020.

08:04 EDT Coty announces resignation of CEO Camillo Pane - Coty announced the resignation of Camillo Pane, current CEO of Coty, for family reasons and the appointment of Pierre Laubies as the new CEO of Coty, effective immediately. This also announces the appointment of Pierre Laubies as a director of Coty, effective immediately. Until recently, Pierre was CEO of Jacob Douwe Egberts, a leading player in the global coffee category. The Board is commencing a renewal process to bring new perspectives to the company and strengthen independent director representation. Specifically, the Board has agreed and started a process to add two new independent Board members with deep commercial and financial experience. In addition, Peter Harf is taking over the chairman role from Bart Becht effective immediately and the Board has decided to appoint Erhard Schoewel as its Lead Independent Director.

07:58 EDT Bombardier and Alstom consortium amends STM contract, order now valued at $340M - The consortium comprising Bombardier (BDRBF) and Alstom (ALSMY) has signed an amendment to the initial acquisition contract of October 2010, concluded with Societe de transport de Montreal, or STM, for the supply of an additional 153 metro cars. The value of this new order is approximately $340M. Bombardier's share is valued at $213M and Alstom's share is valued at $127M. Most of the manufacturing and the total of the final assembly of these additional vehicles will be undertaken at Bombardier's facility in La Pocatiere, in the Bas St-Laurent region of Quebec, where the manufacturing of the last trainsets of STM is being completed, according to the agreed schedule. As with the first phase, Alstom's facility will supply the bogies and the motors, as well as the train control, communication, passenger information and video surveillance systems. Nearly 170 Bombardier employees will be assigned to this new order, which will also involve 70 employees at the Alstom plant in Sorel-Tracy. With 60% Canadian content, this order will leverage a network of several hundred suppliers across Quebec. Through this agreement, STM will benefit from the replacement of part of its fleet at a lower cost. Each trainset can accommodate 8% more passengers, which represents thousands of additional riders annually. In addition, the AZUR metro cars have features that demonstrate their comfort, reliability and safety.

07:54 EDT Athenahealth trading halted, news pending

07:42 EDT NetEase provides update on financing for NetEase Cloud Music - NetEase (NTES) announced that its music streaming platform NetEase Cloud Music has completed its previously announced round of financing with investors, including strategic partner Baidu (BIDU), General Atlantic, Boyu Capital and several other investors. The total amount raised was over $600M, and NetEase remains the controlling shareholder of the NetEase Cloud Music business.

07:37 EDT Ophthotech announces results from Phase 2a safety trial of Zimura - Ophthotech Corporation announced the results from its Phase 2a safety trial of Zimura, the company's complement factor C5 inhibitor, in patients with wet age-related macular degeneration. This trial was designed to evaluate the safety of different dosage regimens of Zimura combination therapy in wet AMD and was the first in human trial assessing the safety of Zimura 4mg dose in combination with Lucentis 0.5mg, an anti-vascular endothelial growth factor. Various dosing regimens of Zimura were administered in combination with Lucentis in patients with wet AMD who have not been previously treated with anti-VEGF drugs. Based on a preliminary analysis of the safety data from this trial, Zimura combination therapy was generally well tolerated after six months of treatment. The most frequently reported ocular adverse events were related to the injection procedure. No adverse events were attributed to Zimura combination therapy. Sixty-four patients were enrolled and treated in this randomized, dose-ranging, open-label, multi-center Phase 2a clinical trial designed to assess the safety of various Zimura dosing regimens in combination with anti-VEGF therapy at month 6 for the treatment of wet AMD. The trial enrolled treatment-naive patients and was designed to allow an assessment of available safety measures, including visual acuity. Patients were enrolled in four groups: In Group 1, 10 patients were administered monthly combination therapy consisting of Lucentis 0.5mg followed by Zimura 4mg two days later. In this group, the mean change in visual acuity from baseline at month 6 was 9.0 ETDRS letters with a median of 7.0 letters. 40% of patients gained greater than or equal to three lines of vision, or 15 ETDRS letters, defined as significant visual gain. In Group 2, 10 patients were administered monthly combination therapy consisting of Lucentis 0.5mg and Zimura 2mg on the same day, which was the same dosing regimen as the best-performing group from the previously completed Phase 1/2a clinical trial. In this group, the mean change in visual acuity from baseline at month 6 was 10.2 ETDRS letters with a median of 16.0 letters. 60% of patients gained greater than or equal to three lines of vision, or 15 ETDRS letters, defined as significant visual gain. In Group 3, during the induction phase, 22 patients were administered Lucentis 0.5mg followed by Zimura 2mg on the same day followed by Zimura 2mg fourteen days later. During a subsequent maintenance phase, patients were administered Lucentis 0.5mg followed by Zimura 2mg on the same day. In this group, the mean change in visual acuity from baseline at month 6 was 10.7 ETDRS letters with a median of 10.0 letters. 40.9% of patients gained greater than or equal to three lines of vision, or 15 ETDRS letters, defined as significant visual gain. In Group 4, during the induction phase 22 patients were administered Lucentis 0.5mg followed by Zimura 2mg on the same day followed by Zimura 2mg fourteen days later. During a subsequent maintenance phase patients were administered Zimura 2mg followed two days later by Lucentis 0.5mg and Zimura 2mg. In this group, the mean change in visual acuity from baseline at month 6 was 9.9 ETDRS letters with a median of 11.0 letters. 18.2% of patients gained greater than or equal to three lines of vision, or 15 ETDRS letters, defined as significant visual gain. Previously, Ophthotech completed a multicenter, ascending dose and parallel group, open-label, first in human Phase 1/2a clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of Zimura given in combination with Lucentis 0.5mg in patients with wet AMD. This trial included a group of patients that received the same dosing and schedule regimen as in Group 2 in the current Phase 2a trial. In the treatment-naive patients who had received all six monthly Zimura 2mg injections in combination with Lucentis 0.5mg in the Phase 1/2a trial, the mean change in visual acuity from baseline at month 6 was 15.3 ETDRS letters with a median of 16.0 letters and 60% of patients had gained greater than or equal to three lines of vision, or 15 ETDRS letters, defined as significant visual gain. Although one needs to be cautious in making comparisons, these results in this earlier Phase 1/2a clinical trial were better than what is generally observed with anti-VEGF monotherapy. All doses in this earlier trial were well tolerated with no adverse events considered to be related to the study drug.

07:37 EDT Pluristem reports additional PLX-PAD data at AHA Scientific Sessions - Pluristem announced that the company presented additional data from its Phase II clinical study evaluating PLX-PAD for the treatment of Intermittent Claudication, or IC, at the American Heart Association, or AHA, Scientific Sessions. Additional analysis of the Phase II IC data confirmed the optimal dosing regimen of PLX-PAD in the treatment of peripheral arterial diseases, or PAD, two administrations of 300 million cells, each originating from a different donor. This is also the treatment regimen being administered to patients in the company's ongoing multinational Phase III study in Critical Limb Ischemia, or CLI, a more severe stage of PAD. Patients treated with PLX-PAD at the optimal dosing regimen showed statistically significant improvement in maximum walking distance, or MWD, at 52 weeks across all sites, nationalities, gender and ethnicity as compared to placebo. These patients also experienced no revascularization events at 65 weeks as compared to 12% occurrence in the placebo group. An additional analysis of the data showed patients treated with PLX-PAD at the optimal dosing regimen demonstrated a significant decrease of 48% in C-reactive protein, or CRP, at 65 weeks, as compared to 95% increase in the placebo group. High levels of CRP, a protein found in blood plasma, is associated with inflammation which is associated with PAD. Moreover, these patients also experienced a statistically significant relative reduction of 7.77 in Hemoglobin A1C at 65 weeks compared to placebo. HbA1c measures the amount of blood sugar attached to hemoglobin. A reduction in HbA1c indicates better glucose control in patients and is the most commonly used measurement to evaluate treatment efficacy in diabetics. PLX-PAD treated patients showed good safety profile in the study as well as a reduction in the incidence of adverse events including malignancies, respiratory events and cardiac disorders.

07:28 EDT Ziopharm, Regeneron announce clinical supply agreement for rGBM treatment - Ziopharm (ZIOP) announced a clinical supply agreement with Regeneron (REGN) to evaluate Ziopharm's Ad-RTS-hIL-12 plus veledimex in combination with Regeneron's PD-1 antibody Libtayo to treat patients with recurrent glioblastoma, or rGBM. Ad-RTS-hIL-12 plus veledimex is an investigational gene therapy designed to induce and control the production of human interleukin 12 that activates the immune system and recruits cancer-fighting T cells into tumors. Libtayo has been approved in the United States for the treatment of patients with metastatic cutaneous squamous cell carcinoma, or CSCC, or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Under the terms of the agreement, Ziopharm and Regeneron will initiate a Phase 2 study in the first half of 2019 in patients with rGBM to measure preliminary safety and efficacy of Ad-RTS-hIL-12 plus veledimex in combination with Libtayo. Ziopharm will be responsible for the conduct and costs of the clinical trial, and Regeneron will supply Libtayo for the study. The companies potentially may explore the Ad-RTS-hIL-12 plus veledimex in combination with Libtayo in additional indications. Regeneron is developing Libtayo both alone and in combination with other therapies for the treatment of various cancers.

07:18 EDT Aptinyx reports results from NYX-2925 studies - Aptinyx announced that exploratory clinical studies of its novel NMDA receptor, or NMDAr, modulator, NYX-2925, provide the first evidence that oral dosing of the product candidate induces pharmacodynamic activities in humans that are understood to be NMDAr-mediated. The two exploratory studies in healthy human volunteers employed electrophysiological measures to assess the pharmacodynamic effects of NYX-2925 at dose levels consistent with those under evaluation in ongoing Phase 2 studies. The findings from these exploratory studies reinforce observations in preclinical mechanistic studies of NYX-2925. The study results validate that NYX-2925 activates NMDAr-mediated pathways, provide further insight into its mechanism of action, and identify potential biomarkers for further investigation. In the first exploratory study, Aptinyx utilized advanced electrophysiology measures in 32 healthy human subjects to evaluate the effects of a single administration of NYX-2925 versus placebo on synaptic plasticity, a biological measure of changes in neural cell communication. Electrical activity within the brain was recorded through multiple electrodes placed on the scalp. This electrical activity can occur at different frequencies and with different magnitude over time. Different patterns observed in response to particular forms of sensory stimuli correspond to activities related to sensory processing, plasticity, learning, and memory. As demonstrated by differences in electroencephalography, or EEG, wave-form responses, administration of NYX-2925 results in robust enhancements in synaptic plasticity. This observed plasticity enhancement, which is consistent with NMDAr pathway activation, was statistically significant two hours following administration and was observed across all dose levels studied. In addition, analysis of time-frequency EEG measures revealed an effect of NYX-2925 on enhanced stimulus processing that persisted for at least seven days. Both the immediate and long-lasting effects on synaptic plasticity are consistent with observations in preclinical studies of NYX-2925. In the second exploratory study, Aptinyx used polysomnography and other measures to evaluate the effects of NYX-2925 on multiple components of sleep, which are also mediated through the NMDAr pathway. Polysomnography evaluates multiple parameters, including electrical activity in the brain. Together, these measures can indicate different states of sleep, including REM and non-REM. Twenty-seven healthy male participants were subjected to sleep disruption and evaluated in a two-arm crossover design study. One arm of the study, in which subjects received NYX-2925 followed by placebo, showed unexpectedly high variability within the small sample size, thus precluding analysis of this arm. However, analysis of the other arm, in which subjects received placebo followed by NYX-2925, showed that NYX-2925 significantly enhanced various measures, including overall sleep duration and non-REM sleep duration. These results are consistent with observations in preclinical studies of NYX-2925 in sleep-disrupted rodents.

07:13 EDT ContraFect appoints Michael Messinger CFO - ContraFect (CFRX) announced the appointment of Michael Messinger as the company's CFO. Messinger previously served as the company's senior VP of finance. Prior to joining the company in 2012, Messinger was director of finance at Lexicon (LXRX), where he was responsible for the financial management of Lexicon's partnership with Symphony Capital, in addition to fiscal coordination and project management concerning Lexicon's development programs.

07:11 EDT Aecom sees restructuring costs of $80M-$90M in FY19 - AECOM expects the G&A reduction program to deliver $140 million of annual run-rate cost savings, net of any leakage and reinvestment, by the end of fiscal year 2021. Of the gross amount, the majority has already been actioned since the beginning of the fiscal year. The Company expects to incur restructuring costs of $80 to $90 million in fiscal 2019, the majority of which will occur in the first half of the fiscal year and will be excluded from the Company's adjusted results. Total cash costs for the restructuring are expected to be between $60 and $70 million. Also included in the Company's fiscal 2019 guidance is approximately $13 million of adjusted EBITDA from AECOM Capital contributions.

07:10 EDT Akcea, Ionis say Phase 2 study in patients with elevated Lp(a) met endpoints - Akcea Therapeutics (AKCA) and Ionis Pharmaceuticals (IONS) announced that data from the Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), were presented in a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10. The study met all primary and secondary efficacy endpoints analyzed at 6 months. Approximately 98% of patients in the 20mg weekly cohort and approximately 81% of patients in the 60mg every 4 week cohort achieved clinically significant reductions in Lp(a) levels bringing them below the recommended threshold of risk for CVD events. Treatment with AKCEA-APO(a)-LRx was associated with decreases in LDL-C, apoB, OxPL-apoB, OxPL-apo(a). Most adverse events were mild. The most frequent adverse events were injection site reactions. ISRs occurred in 26% of patients and were mostly mild and one patient discontinued due to an ISR. There were no safety concerns related to platelet counts, liver function or renal function. "These data show that AKCEA-APO(a)-LRx significantly reduces Lp(a) in patients with pre-existing cardiovascular disease due to elevated Lp(a) levels. AKCEA-APO(a)-LRx is the first and only drug to show a clinically significant reduction of Lp(a) levels and a favorable safety and tolerability profile in patients with this genetic condition," said Dr. Louis O'Dea, chief medical officer at Akcea Therapeutics. "This is a particularly important advancement as elevated Lp(a) can cause cardiac events for patients as early as in their 30s and 40s. We are actively working with Novartis to prepare for an end of Phase 2 meeting with FDA. We look forward to advancing this important development program into Phase 3."

07:08 EDT Rexford Industrial acquires two industrial properties for $40.3M - Rexford Industrial announced the acquisition of two industrial properties for $40.3M. The acquisitions were funded using available cash on hand.

07:07 EDT Del Frisco's sees FY18 comparable restaurant sales down 1.5% to up 0.5% - Sees FY18 adjusted EBITDA of $34M-$38M.

07:05 EDT Concert Pharmaceuticals reports 'positive' CTP-543 results in Phase 2a trial - Concert Pharmaceuticals announced interim topline results from the first two cohorts of its Phase 2a trial evaluating its investigational treatment CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss. At 24 weeks, patients treated with an 8 mg twice-daily dose of CTP-543 met the primary efficacy endpoint vs. placebo. At this dose, significant differences from placebo were observed beginning at Week 12. Regrowth of hair did not appear to plateau at Week 24. Treatment with CTP-543 was generally well tolerated. Dosing in a 12 mg twice-daily cohort is currently underway. Complete study results are expected to be presented at a future medical meeting. The primary efficacy endpoint in the 8 mg twice-daily cohort was met with 47% of patients achieving a greater than or equal to 50% relative reduction in their overall severity of alopecia tool score from baseline compared to placebo. For the 4 mg cohort, 21% of patients achieved a greater than or equal to 50% relative reduction in their overall SALT score from baseline, however these differences were not significantly different from placebo. In the primary analysis, the response observed in the 8 mg twice-daily dose was significantly different than the 4 mg twice daily dose. The average baseline SALT score across all patients enrolled in the trial was approximately 88. Compared to placebo, a significant relative reduction in mean SALT score was first observed in the 8 mg cohort at Week 12. The most common side effects in the trial were headache, upper respiratory tract infection, cough, acne and nausea. No serious adverse events were reported. The Phase 2a trial is a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata. Patients will be randomized to receive one of three doses of CTP-543 or placebo twice-daily. The final cohort evaluating a 12 mg twice-daily dose of CTP-543 compared to placebo is ongoing. The primary outcome measure will utilize the severity of alopecia tool after 24 weeks of dosing. Results from the complete Phase 2a trial, including the 12 mg cohort, are expected in the third quarter of 2019.

07:02 EDT AstraZeneca, Merck: FDA accepts sNDA for LYNPARZA - AstraZeneca (AZN) and Merck (MRK) announced that the U.S. FDA has accepted a supplemental New Drug Application for priority review for the approval of LYNPARZA tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated advanced ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. A Prescription Drug User Fee Act date is set for the first quarter of 2019. This is the first U.S. regulatory submission acceptance for a poly ADP-ribose polymerase inhibitor in the first-line maintenance setting for advanced ovarian cancer, and, if approved, will be the fourth indication for LYNPARZA in the U.S.

06:58 EDT Aecom sees FY19 adjusted EBITDA $920M-$960M - Sees: Fiscal 2019 adjusted EBITDA guidance of $920 - $960 million reflects 12% growth at the mid-point as compared to fiscal 2018, which demonstrates the expected strong payback on the above initiatives. A more profitable and lower-risk business profile, combined with the Company's capital allocation policy focused on shareholder returns, including $850 million remaining under the $1 billion Board stock repurchase authorization, is expected to result in consistently strong financial performance and shareholder value creation.

06:43 EDT UPS, Teamsters Union representing UPS Freight workers agree to five-year deal - Workers at UPS Freight represented by the Teamsters Union have ratified a new five-year agreement that was the company's last, best and final offer, averting a national strike. Members approved the contract by a 77% to 23% margin at local union meetings held from November 7 until November 11. The agreement covers approximately 11,600 workers at the company. The final vote was 6,935 in favor and 2,067 opposed with 84%of eligible members voting.

06:36 EDT Acorn International's Babaka brand gross revenue reaches RMB13.6M on Singles Day - Acorn International announced that its Singles Day e-commerce performance for its Babaka brand exceeded gross revenue of RMB8.5M in the first two hours of shopping and ended the day at about RMB13.6M up from RMB7.8M for the full day last year. New product category entrant Acorn Fresh, selling frozen seafood to Chinese consumers, also performed well on its inaugural Singles Day selling day and other parts of the business also had a strong day of sales.

06:31 EDT Cable ONE to acquire Clearwave Communications in all-cash transaction - Cable One announced it has entered into a definitive agreement to acquire Clearwave Communications, a facilities-based service provider that owns and operates a high-capacity fiber network offering dense regional coverage in Southern Illinois. The acquisition provides Cable ONE with a premier fiber network within its existing footprint and further enables the Company to supply its customers with enhanced business services solutions. The acquisition will also provide a platform to allow Cable ONE to replicate Clearwave's strategy in several of the Company's existing markets. Clearwave has more than 2,400 route miles of dense metro fiber infrastructure connecting approximately 2,700 on-net businesses, towers and data centers. Clearwave is headquartered in Harrisburg, Illinois, and is majority-owned by funds affiliated with Stephens Capital Partners LLC, the private equity arm of Stephens Inc. based in Little Rock, Arkansas. The all-cash transaction is expected to be funded through Cable ONE's cash on hand and its existing revolving credit facility. The transaction is subject to certain regulatory approvals and other customary closing conditions and is expected to be completed during the first quarter of 2019.

06:05 EDT CollPlant closes worldwide license agreement with United Therapeutics - CollPlant (CLGN) announced the closing of a worldwide exclusive license, development and commercialization agreement with United Therapeutics (UTHR) for 3D bioprinted lung transplants. Effectiveness of the agreement was subject to certain closing conditions which were all achieved, and the agreement became effective on November 9. As previously announced, CollPlant granted United Therapeutics, through its wholly owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, an exclusive license to its technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants throughout the universe. CollPlant will manufacture and supply BioInk for a few years to meet development process demand, and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk. In addition to the initial focus on lung manufacturing, the agreement grants United Therapeutics an option, exercisable for two years, to expand the field of its license to add up to three additional organs.

05:39 EDT RADA Electronic announces $12M in new orders - RADA Electronic announced the receipt of over $12M in new orders, in recent weeks. Out of these, over $5M were orders for RADA's software-defined radars for counter rocket artillery and mortar, counter UAV and short range air defense. The majority of these orders were from new and strategic defense organizations, and these orders represent initial orders with potential for much greater follow-on orders in the future. Portions of the orders were follow-ons from customers that have placed initial orders earlier this year. Almost $7 million out of the $12 million, were follow-on orders for RADA's legacy avionics, including avionics for UAVs, helicopters, digital video recorders, and ongoing maintenance orders for RADA's wide installment base of core avionics for military platforms.

05:23 EDT Johnson & Johnson enters $26.35M research collaboration with SNEC, SERI - The Singapore National Eye Centre, or SNEC, the Singapore Eye Research Institute, or SERI, and Johnson & Johnson Vision announced a $26.35M research collaboration to tackle myopia, or nearsighted vision, the largest threat to eye health this century. By 2050, half of the world's population are projected to be myopic, with one billion expected to have high myopia, a severe state of the condition that can lead to retinal disease with an increased risk of blindness. The first-of-its-kind public-private strategic partnership in Asia focused on myopia will create a deeper understanding of how the condition develops, how it progresses and how it may be intercepted. It will focus on developing predictive tools to identify those who may be at risk to develop high myopia, conduct research on the underlying mechanisms of myopia, progress novel therapies, and discover and validate methods to prevent the onset and progression of the condition.

05:18 EDT Correction: Black Box to be acquired for $1.08 per share

05:16 EDT Black Box to be acquired by AGC Networks for $1.07 per share - A wholly-owned subsidiary of global solutions integrator AGC Networks, AGC Networks Pte. Ltd. in Singapore and Black Box announced that they have entered into a definitive merger agreement under which AGC Singapore would acquire all the outstanding shares of Black Box for $1.08 per share in cash, subject to customary closing conditions and regulatory approvals. The Black Box Board of Directors unanimously approved the merger agreement following a thorough review of the full range of available strategic, financial and capital structure alternatives, which Black Box commenced and announced on February 6, 2018. The transaction is expected to close prior to the end of the calendar year. The combination with Black Box will provide a substantial increase in AGC's presence and offerings in North America. In addition, AGC will enhance its footprint in providing technologies and services throughout six continents. The acquisition will be significant for AGC, expected to add over $600 million in annual revenue and approximately 3,000 team members serving clients worldwide. Under the terms of the merger agreement, an indirect wholly owned U.S. subsidiary of AGC Singapore will commence a tender offer to purchase all of the outstanding shares of Black Box common stock for $1.08 per share in cash. Upon the successful completion of the tender offer, the U.S. subsidiary of AGC Singapore would acquire all remaining shares of common stock not tendered in the offer for $1.08 per share through a second-step merger. The tender offer and the second-step merger are subject to customary conditions, including the tender of a majority of the outstanding shares of Black Box common stock. The U.S. subsidiary of AGC Singapore is financing the merger through a combination of equity and debt. Pathlight Capital will serve as administrative agent for the senior credit facilities.